AXCELLA TO PRESENT AT UPCOMING INVESTOR CONFERENCES

-25TH ANNUAL CREDIT SUISSE HEALTHCARE CONFERENCE -

-STIFEL 2016 HEALTHCARE CONFERENCE-

CAMBRIDGE, Mass., Oct. 26, 2016 – Axcella, a biotechnology company pioneering transformative medicines for patients with conditions where disrupted amino acid biology plays a critical role, announced today that Robert Connelly, President and Chief Executive Officer, will participate in the following upcoming investor conferences:

  • 25th Annual Credit Suisse Healthcare Conference in Scottsdale, Arizona, with a presentation on November 7, 2016, at 1:30 p.m. MST

  • Stifel 2016 Healthcare Conference in New York, NY, with a presentation on November 15, 2016 at 11:45 a.m. EST

About Axcella Health
Axcella Health is pioneering revolutionary new medicines with a focus on amino acid homeostasis. The company has discovered more than 2,000 diseases with amino acid imbalances and developed a systems pharmacology approach to restore health at the cellular level. Axcella’s proprietary platform is clinically validated across several indication areas, with clinical-stage candidates in muscle, neurodegenerative and liver conditions. Axcella is led by a team with a strong track record of leaving a lasting impact on the therapeutic landscape through the development of novel products. The company was founded by VentureLabs, the Innovation Foundry at Flagship Ventures, and has received additional funding from Fidelity Research & Management Group, Gurnet Point Capital and Nestlé Health Science. Axcella is based in Cambridge, Mass. For more information, visit www.axcellahealth.com.

Media Contact
Dan Quinn, Ten Bridge Communications
dan@tenbridgecommunications.com
781-475-7974

Company Contact
Christine Lafontant
clafontant@axcellahealth.com
857-320-2250